AstraZeneca (LON:AZN) Given Sell Rating at Deutsche Bank Aktiengesellschaft

Key Points

• Deutsche Bank reissued a sell rating on AstraZeneca with a £115 target, implying about a 15.3% downside from the company's current price.
• Despite that, the analyst consensus is a Moderate Buy—five analysts rate the stock Buy and one Sell—with a consensus target price of £153.33.
• AstraZeneca shares traded up 1.8% to £135.76 on heavy volume (154.6m vs. avg. 31.9m), with a market cap of £210.5bn and a P/E ratio of 20.45.

AstraZeneca (LON:AZN - Get Free Report)'s stock had its "sell" rating reissued by equities research analysts at Deutsche Bank Aktiengesellschaft in a research report issued to clients and investors on Wednesday,Digital Look reports. They currently have a £115 target price on the biopharmaceutical company's stock. Deutsche Bank Aktiengesellschaft's target price would indicate a potential downside of 15.29% from the company's current price.

Other research analysts also recently issued reports about the stock. Shore Capital Group reissued a "buy" rating on shares of AstraZeneca in a research report on Friday, January 16th. Berenberg Bank boosted their price objective on shares of AstraZeneca from £145 to £160 and gave the company a "buy" rating in a research report on Tuesday, January 27th. Jefferies Financial Group reissued a "buy" rating and set a £180 price objective on shares of AstraZeneca in a research report on Friday, April 10th. Citigroup boosted their price objective on shares of AstraZeneca from £170 to £180 and gave the company a "buy" rating in a research report on Friday, April 10th. Finally, JPMorgan Chase & Co. reissued an "overweight" rating on shares of AstraZeneca in a research report on Thursday, January 15th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of £153.33.

AstraZeneca Trading Up 1.8%

AstraZeneca stock traded up GBX 246 during mid-day trading on Wednesday, reaching £135.76. 154,623,859 shares of the company traded hands, compared to its average volume of 31,940,236. The company has a debt-to-equity ratio of 71.66, a current ratio of 0.91 and a quick ratio of 0.59. The firm's 50 day moving average price is £146.29 and its 200 day moving average price is £139.94. The firm has a market capitalization of £210.54 billion, a price-to-earnings ratio of 20.45, a P/E/G ratio of 0.86 and a beta of 0.28. AstraZeneca has a 52-week low of GBX 9,651 and a 52-week high of £157.32.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.